• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    12/20/22 4:22:37 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email
    SC 13G/A 1 tm22331061_sc13ga.htm SC 13G/A

     

     

     

    SECURITIES & EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2

     

    (Amendment No. 1)*

     

     

     

    Hyperfine, Inc.
    (Name of Issuer)

     

    Class A common stock

    (Title of Class of Securities)

     

    44916K106

    (CUSIP Number)

     

    December 31, 2021**

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

     

    ¨       Rule 13d-1(c)

     

    x      Rule 13d-1(d)

     

    (Page 1 of 9 Pages)

     

     

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** This Amendment No. 1 to Schedule 13G is being filed to correct the number of Class A Shares reported as beneficially owned by the Reporting Persons as of December 31, 2021, to include 100,000 shares held through HC Affiliates and 591,650 shares held in separately managed accounts that were inadvertently omitted from the original statement.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 44916K106 13G Page 2 of 9 Pages

     

    (1)

    NAMES OF REPORTING PERSONS

     

    HC Sponsor LLC 

    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a) ¨         (b) ¨

    (3) SEC USE ONLY
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands 

    NUMBER OF
    SHARES
    BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON WITH
    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER

     

    6,634,000(1) 

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER

     

    6,634,000(1) 

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,634,000(1) 

    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES(see instructions) ¨ 
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    12.0%(2) 

    (12)

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC and 1,100,000 Class A Shares held by the HC Affiliates.

     

    (2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

     

     

     

    CUSIP No. 44916K106 13G Page 3 of 9 Pages

     

    (1)

    NAMES OF REPORTING PERSONS

     

    HealthCor Group, LLC 

    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a) ¨         (b) ¨

    (3) SEC USE ONLY
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

    NUMBER OF
    SHARES
    BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON WITH
    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER

     

    6,634,000(1) 

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER

     

    6,634,000(1) 

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,634,000(1) 

    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES(see instructions) ¨ 
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    12.0%(2) 

    (12)

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC and 1,100,000 Class A Shares held by the HC Affiliates.

     

    (2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

     

     

     

    CUSIP No. 44916K106 13G Page 4 of 9 Pages

     

    (1)

    NAMES OF REPORTING PERSONS

     

    Arthur Bruce Cohen

    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a) ¨         (b) ¨

    (3) SEC USE ONLY
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON WITH
    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER

     

    7,225,650(1) 

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER

     

    7,225,650(1) 

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,225,650(1) 

    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES(see instructions) ¨ 
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.1%(2) 

    (12)

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

    (1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC, 1,100,000 Class A Shares held by the HC Affiliates and 591,650 Class A Shares held by separately managed accounts.

     

    (2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

     

     

     

    CUSIP No. 44916K106 13G Page 5 of 9 Pages

     

    (1)

    NAMES OF REPORTING PERSONS

     

    Joseph Patrick Healey

    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a) ¨         (b) ¨

    (3) SEC USE ONLY
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY OWNED BY
    EACH
    REPORTING
    PERSON WITH
    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER

     

    7,225,650(1) 

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER

     

    7,225,650(1) 

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,225,650(1) 

    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES(see instructions) ¨ 
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.1%(2) 

    (12)

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

    (1) Represents 5,534,000 Class A Shares held directly by HC Sponsor LLC, 1,100,000 Class A Shares held by the HC Affiliates and 591,650 Class A Shares held by separately managed accounts.

     

    (2) Calculated based on 55,277,061 Class A Shares outstanding as of December 31, 2021, as reported on the Issuer’s final prospectus filed pursuant to Rule 424(b)(3) with the SEC on February 1, 2022.

     

     

     

    CUSIP No. 44916K106 13G Page 6 of 9 Pages

     

    Item 1(a). Name of Issuer:
       
      Hyperfine, Inc.  
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      351 New Whitfield Street
    Guilford, CT 06437
       
    Item 2(a, b, c). Names of Persons Filing:
       
      (i) HC Sponsor LLC, 55 Hudson Yards, 28th Floor, New York NY 10001;
         
      (ii) HealthCor Group, LLC, 55 Hudson Yards, 28th Floor, New York NY 10001;
         
      (iii) Joseph Healey, 55 Hudson Yards, 28th Floor, New York, NY 10001;
         
      (i) Arthur Cohen, 12 South Main Street, #203 Norwalk, CT 06854;
         
      Both Mr. Healey and Mr. Cohen are United States citizens.
       
      The persons at (i) through (iv) above are collectively referred to herein as the “Reporting Persons”.

     

     

     

    CUSIP No. 44916K106 13G Page 7 of 9 Pages

     

    Item 2(d). Title of Class of Securities
       
      Class A common stock
       
    Item 2(e). CUSIP Number
       
      44916K106
       
    Item 3. Not applicable.
     
    Item 4.Ownership.
        
    (a)Amount beneficially owned:
     See responses to Item 9 on each cover page.
    (b)Percent of Class:
     See responses to Item 11 on each cover page.
    (c)Number of shares as to which the Reporting Person has:
       (i)Sole power to vote or to direct the vote:
       See responses to Item 5 on each cover page.
      (ii)Shared power to vote or to direct the vote:
       See responses to Item 6 on each cover page.
      (iii)Sole power to dispose or to direct the disposition of:
       See responses to Item 7 on each cover page.
      (iv)Shared power to dispose or to direct the disposition of:
       See responses to Item 8 on each cover page.

     

    HC Sponsor LLC (the “Sponsor”) directly holds 5,534,000 Class A Shares (the “Founder Shares”) and entities affiliated with the Sponsor (the “HC Affiliates”) directly hold 1,100,000 Class A Shares, of which 1,000,000 Class A Shares were purchased in a private placement (the “PIPE Shares”). The Sponsor is managed by its manager, HealthCor Sponsor Investments LLC, which is managed by its manager, HealthCor Group, LLC, which also indirectly manages the HC Affiliates. Arthur Cohen and Joseph Healey are the controlling members of HealthCor Group, LLC. In addition, separately managed accounts (the “SMAs”) managed by HealthCor Management, L.P. own 591,650 Class A Shares. Messrs. Cohen and Healey are the managers of the general partner of HealthCor Management, L.P. As such, Messrs. Cohen and Healey have voting and investment discretion with respect to the securities held by each of HC Sponsor LLC, the HC Affiliates and the SMAs but disclaim beneficial ownership of such securities. The filing of this Statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by this Statement.

     

    Item 5.Ownership of Five Percent or Less of a Class:
      
     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

     

     

    CUSIP No. 44916K106 13G Page 8 of 9 Pages

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not Applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group.
       
      See Exhibit I.
       
    Item 9. Notice of Dissolution of Group.
       
      Not Applicable
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibits:

     

    Exhibit I:Joint Acquisition Statement

     

     

     

    CUSIP No. 760873109 13G Page 9 of 9 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATED: December 20, 2022

     

      HC Sponsor LLC
         
        /s/ Arthur Cohen
        Name: Arthur Cohen
        Title: Authorized Signatory
         
      HealthCor Group, LLC
         
        By: HealthCor Group, LLC, its general partner
         
        /s/ Arthur Cohen
        Name: Arthur Cohen
        Title: Authorized Signatory
         
      JOSEPH HEALEY, Individually
        /s/ Joseph Healey
         
      ARTHUR COHEN, Individually
        /s/ Arthur Cohen

     

     

     

    EXHIBIT I

     

    JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated:         December 20, 2022

     

      HC Sponsor LLC
         
        /s/ Arthur Cohen
        Name: Arthur Cohen
        Title: Authorized Signatory
         
      HealthCor Group, LLC
         
        By: HealthCor Group, LLC, its general partner
         
        /s/ Arthur Cohen
        Name: Arthur Cohen
        Title: Authorized Signatory
         
      JOSEPH HEALEY, Individually
        /s/ Joseph Healey
         
      ARTHUR COHEN, Individually
        /s/ Arthur Cohen

     

     

     

    Get the next $HYPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Operating Officer Teisseyre Thomas sold $3,497 worth of shares (3,238 units at $1.08), decreasing direct ownership by 4% to 84,989 units (SEC Form 4)

      4/A - Hyperfine, Inc. (0001833769) (Issuer)

      2/20/25 5:23:21 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Teisseyre Thomas sold $3,884 worth of shares (3,237 units at $1.20), decreasing direct ownership by 4% to 84,990 units (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      2/18/25 7:03:33 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Teisseyre Thomas sold $2,380 worth of shares (2,800 units at $0.85), decreasing direct ownership by 3% to 88,227 units (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      11/18/24 5:41:50 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

      4/29/25 4:28:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Enrolls Initial Patients in NEURO PMR Study to Evaluate Use of AI-Powered Portable MRI in Neurology Offices

      Real-world study will assess clinical utility and patient experience across diverse neurological conditions to support adoption of AI-powered portable MRI systems in the office setting. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system, first approved in 2021—today announced the enrollment of initial patients in the NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study. The NEURO PMR study is the first multi-center, prospective observational study of its kind, comparing portable ultra-low-field MRI and

      4/15/25 4:00:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update. "I am pleased with the many milestones we achieved in the fourth quarter of 2024. These set the stage well for us to execute on our expansion plan, drive accelerated growth across multiple sites of care globally and meaningfully reduce cash burn in 2025," said Maria Sainz, Chief Executive Officer and President of Hyperfine,

      3/17/25 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hyperfine Inc.

      SC 13G - Hyperfine, Inc. (0001833769) (Subject)

      2/13/24 5:06:19 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      2/14/23 4:07:09 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      12/20/22 4:22:37 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Financials

    Live finance-specific insights

    See more
    • Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

      4/29/25 4:28:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

      3/4/25 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

      GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

      11/12/24 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    SEC Filings

    See more
    • Hyperfine Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/2/25 4:08:40 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by Hyperfine Inc.

      DEFA14A - Hyperfine, Inc. (0001833769) (Filer)

      4/7/25 4:06:35 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Hyperfine Inc.

      DEF 14A - Hyperfine, Inc. (0001833769) (Filer)

      4/7/25 4:05:07 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hyperfine downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

      8/11/22 6:32:27 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI initiated coverage on Hyperfine with a new price target

      Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

      5/31/22 7:16:51 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Wells Fargo initiated coverage on Hyperfine with a new price target

      Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

      4/14/22 7:32:25 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

      Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

      12/3/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

      Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

      5/28/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care